My daughter’s annual pharmacy bill is routinely a multiple of my salary as a state employee whose family relies on the health benefits that come with my job. That grim ...

If you have trouble affording prescription drugs, some independent pharmacists say that so-called pharmacy middlemen are ...

At the forefront is its blockbuster immuno-oncology drug, Opdivo, complemented by heavy hitters like Revlimid, Pomalyst, ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

Bristol Myers Squibb’s third-quarter results benefited from sales of its legacy brands Eliquis and Revlimid, as well as ...

Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of established ...

Two of its biggest sellers — Eliquis and cancer immunotherapy Opdivo — will lose patent exclusivity in the coming years. Cancer blockbuster Revlimid has been suffering from generic competition, while ...

Legacy Portfolio revenues were primarily driven by higher demand for Eliquis, partially offset by a decline in demand for Sprycel due to generic erosion. Eliquis sales reached $3 billion from $2. ...

sales are likely to have been hurt by generic competition in some international markets due to the loss of patent exclusivity. The Zacks Consensus Estimate for alliance revenues from Eliquis is $1 ...

One of the most impactful changes under the Biden-Harris Administration has been the cap on out-of-pocket drug costs for Medicare Part D enrollees, set at $2,000 annually starting in 2025.

Federal officials have celebrated a striking drop in drug overdoses across the country. But state-level data shows that Black people are suffering significantly worse outcomes than white people.